Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trialMarket Watch • 11/11/24
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock SurgesBenzinga • 11/11/24
Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024Business Wire • 11/11/24
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market SetbacksBenzinga • 11/08/24
Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains24/7 Wall Street • 11/02/24
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024Business Wire • 10/31/24
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS ViewZacks Investment Research • 10/31/24
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 10/31/24
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 10/31/24
Bristol Myers's stock pops as earnings top estimates and company raises guidanceMarket Watch • 10/31/24
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises GuidanceInvestors Business Daily • 10/31/24
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugsCNBC • 10/31/24
Curious about Bristol Myers (BMY) Q3 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 10/28/24
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024Business Wire • 10/28/24